Foam cell specific Liver X Receptor (LXR) alpha agonist, SIRT1 inhibitors as well as p300 inhibitors as pharmaceutically active agents

摘要

The present invention relates to compound (I) and its stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable other LXR± agonist, carrier, excipient and/or diluents. Said compound (I), an LXR± agonist has been identified as useful for the prophylaxis and treatment of atherosclerosis and cardiovascular diseases. Further, the present invention refers to compound (II) and its stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said compound (II), a SIRT1 inhibitor has been identified as useful for the prophylaxis and treatment of neurodegenerative diseases or cancer. Furthermore, the present invention discloses compound (III) and its stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said compound (III), a p300 inhibitor has been identified as useful for the prophylaxis and treatment of cancer, metabolic, inflammatory, neurodegenerative or cardiovascular diseases.